Bharat Biotech completed clinical trials of the nasal vaccine with about 4,000 volunteers and there is no side effect or adverse reaction reported so far...

Scientists have described the identification and therapeutic evaluation of an antibody that broadly neutralizes major variants of SARS-CoV-2, including the alpha, beta, delta, and omicron variants.

Russian director Kirill Serebrennikov has been invited to back-to-back Cannes for his latest work, premiering Petrov's Flu last year and Tchaikovsky's Wife this...

Moderna has dosed the first participants in a Phase 3 study of the company’s seasonal influenza vaccine candidate, mRNA-1010....

No one knows exactly what this will look like—only that it’s guaranteed to keep happening.

"There are no new, large mutations that could account for the change in [monkeypox] transmission," says virologist Heather Koehler.

A study that clarifies how some harmless moles grow into deadly melanomas could lead to new drug targets for the successful treatment of cancer.

A rapid decline in sense of smell during a period of normal cognition predicted multiple features of Alzheimer's disease, report researchers.

The Canadian Food Inspection Agency has confirmed 13 positive cases of highly pathogenic avian influenza in Newfoundland since May...

Amid a steady rise in monkeypox cases worldwide, an expert explains how the virus is transmitted, who is at risk, and how vaccines can control the spread.

A new patch "has the potential to offer a new—and more effective—weapon in our arsenal, at a time where new variants are mutating at a rapid rate."...

Porcine circovirus type 3 (PCV3) was first detected in 2016 and has been recorded in many pig-producing countries around the world. PCV3 was quickly reported in Vietnamese pig farms. PCV3 was found in complex cases with multiple clinical syndromes in swine.

A scramble for monkeypox vaccines is under way, with 35 countries vying for access to the 16.4m doses that exist so far, according to the World Health...

bioRxiv - the preprint server for biology, operated by Cold Spring Harbor Laboratory, a research and educational institution...

OBJECTIVES: Patients with liver disease frequently require hospitalisation with infection often the trigger. Influenza vaccination is an effective infection prevention strategy in healthy and elderly but is often perceived less beneficial in patients with liver disease. We investigated whether influenza vaccination triggered serological response and prevented hospitalisation and death in liver disease.DESIGN: Systematic review and meta-analysis.DATA SOURCES: MEDLINE, EMBASE, PubMed and CENTRAL up to January 2019.ELIGIBILITY CRITERIA: Randomised or observational studies of the effects of influenza vaccine in adults with liver disease.DATA EXTRACTION AND SYNTHESIS: Two reviewers screened studies, extracted data and assessed risk of bias and quality of evidence. Primary outcomes were all-cause hospitalisation and mortality. Secondary outcomes were cause-specific hospitalisation and mortality, and serological vaccine response. Random-effects meta-analysis was used to estimate pooled effects of vaccination.RESULTS: We found 10 041 unique records, 286 were eligible for full-text review and 12 were included. Most patients had viral liver disease. All studies were of very low quality. Liver patients both with and without cirrhosis mounted an antibody response to influenza vaccination, and vaccination was associated with a reduction in risk of hospital admission from 205/1000 to 149/1000 (risk difference -0.06, 95% CI -0.07 to 0.04) in patients with viral liver disease. Vaccinated patients were 27% less likely to be admitted to hospital compared with unvaccinated patients (risk ratio 0.73, 95% CI 0.66 to 0.80). No effect against all-cause or cause-specific mortality or cause-specific hospitalisation was found.CONCLUSIONS: The low quantity and quality of the evidence means that the protective vaccine effect may be uncertain. Considering the high risk of serious health outcomes from influenza infection in patients with liver disease and the safety and low cost of vaccination, overall, the potential benefits of seasonal vaccination both to patients and the healthcare systems are likely to outweigh the costs and risks associated with vaccination.PROSPERO REGISTRATION NUMBER: CRD42017067277.

SARS-CoV-2 is not the first virus to cause unexplained chronic illness, but the sheer size of this pandemic means more people will develop long COVID.

bioRxiv - the preprint server for biology, operated by Cold Spring Harbor Laboratory, a research and educational institution...

New research is "a step forward in understanding viral infection pathways and paves the way for research toward better treatments in the future."...

A new universal flu vaccine protects against influenza B viruses, offering broad defense against different strains and improved immune protection, according to a new study by researchers in the Institute for Biomedical Sciences at Georgia State University.

Bats can teach us a lot about how to manage, and maybe even prevent, future pandemics, researchers say.

Researchers have developed a nanobody that can get through the tough exterior of mouse brain cells and untangle misshapen proteins.

In this systematic review and network meta-analysis, all 4 antiviral agents assessed were associated with shortening TTAS; zanamivir was associated with the shortest TTAS, and baloxavir was associated with reduced rate of influenza-related complications.

Healthy subjects <45 years old (young adults) or >65 (elderly adults) were randomized in double-blind fashion to receive intramuscularly subv...

New research suggests microparticles able to release their payloads at different times could form the basis of self-boosting vaccine courses.